Sesquiterpenes from Artemisia argyi: Absolute Configurations
v), to give fourteen subfractions (F9a–F9n). F9m (21 g) was chro-
matographed on a reversed-phase C18 silica gel column, with elu-
tion with MeOH/H2O (3:2, 4:1, 9:1, and 1:0 v/v), to yield seven
subfractions (F9m1–F9m7). F9m1 (4.1 g) was separated again on
a reversed-phase C18 silica gel column with elution with a gradient
of MeOH/H2O (3:2, 4:1, 9:1, and 1:0 v/v) to give ten subfractions
(F9m1a–F9m1j).
spectroscopy. The acylation reaction was found to be complete af-
ter 8 h. 1H NMR spectroscopic data for the (S)-MTPA ester deriva-
tive (1s) of 1 (500 MHz, [D5]pyridine): δ = 6.297 (d, J = 3.5 Hz, 1
H, 13a-H), 6.256 (m, 1 H, 2-H), 5.752 (d, J = 3.0 Hz, 1 H, 13b-H),
5.724 (q, J = 1.4 Hz, 1 H, 3-H), 5.259 (ddd, J = 9.5, 5.0, 3.5 Hz, 1
H, 8-H), 5.162 (d, J = 2.0 Hz, 1 H, 14a-H), 5.074 (d, J = 2.0 Hz,
1 H, 14b-H), 4.234 (dd, J = 10.5, 9.5 Hz, 1 H, 6-H), 3.369 (d, J =
9.5, 6.0 Hz, 1 H, 1-H), 3.290 (m, 1 H, 7-H), 2.948 (t, J = 9.5 Hz, 1
H, 5-H), 2.924 (dd, J = 14.5, 5.0 Hz, 1 H, 9β-H), 2.581 (dd, J =
14.5, 3.5 Hz, 1 H, 9α-H), 2.174 (s, 3 H, -OAc), 1.869 (s, 3 H, 15-
H) ppm.
F9m1e (840 mg) was repeatedly purified by semipreparative HPLC
(25% CH3CN/H2O, 2 mL min–1) to yield compound 15 (7.5 mg, tR
= 30 min). F9m1f (780 mg) was purified by semipreparative HPLC
(25% CH3CN/H2O, 2 mL min–1) to yield compounds 1 (4.1 mg, tR
= 23 min), 13 (2.0 mg, tR = 34 min), and 10 (5.1 mg, tR = 37 min).
F9m1d (800 mg) was purified by semipreparative HPLC (25%
CH3CN, 2 mLmin–1) to yield compounds 14 (1.7 mg, tR = 19 min),
16 (3.8 mg, tR = 25 min), and 2 (8.3 mg, tR = 28 min).
In the same manner, another portion of compound 1 (0.45 mg) was
treated with (S)-MTPA chloride (5 μL) in a second NMR tube at
room temperature for 8 h and in deuterated pyridine (0.5 mL) as
solvent, to afford the (R)-MTPA derivative of 1 (1r). 1H NMR
spectroscopic data for 1r (500 MHz, [D5]pyridine): δ = 6.305 (d, J
= 3.5 Hz, 1 H, 13a-H), 6.281 (m, 1 H, 2-H), 5.796 (q, J = 1.4 Hz,
1 H, 3-H), 5.756 (d, J = 3.1 Hz, 1 H, 13b-H), 5.248 (ddd, J = 9.5,
5.0, 3.5 Hz, 1 H, 8-H), 5.010 (d, J = 2.0 Hz, 1 H, 14a-H), 5.007 (d,
J = 2.0 Hz, 1 H, 14b-H), 4.229 (dd, J = 10.5, 9.5 Hz, 1 H, 6-H),
3.244 (d, J = 9.5, 6.0 Hz, 1 H, 1-H), 3.274 (m, 1 H, 7-H), 2.969 (t,
1 H, J = 9.5 Hz, 5-H), 2.928 (dd, J = 14.5, 5.0 Hz, 1 H, 9β-H),
2.557 (dd, J = 14.5, 3.5 Hz, 1 H, 9α-H), 2.173 (s, 3 H, -OAc), 1.926
(s, 3 H, 15-H) ppm.
F9l (23 g) was transferred to a reversed-phase C18 silica gel column
and eluted with MeOH/H2O (9:11, 3:2, 3:1, and 9:1 v/v) to produce
four subfractions (F9l1–F9l4). F9l1 (7.2 g) was further fractioned
on Sephadex LH-20 with elution with MeOH to give two subfrac-
tions (F9l1a and F9l1b); subfraction F9l1a was crystallized with
methanol to afford compound 17 (201 mg).
F9k (31 g) was chromatographed on a reversed-phase C18 silica gel
column, with elution with MeOH/H2O (2:3, 3:2, and 4:1 v/v) to
yield three subfractions (F9k1–F9k3). Compound 18 (490 mg) was
crystallized with methanol from subfraction F9k1 (10 g) during
evaporation at room temperature. F9k3 (7.3 g) was fractioned on
Sephadex LH-20 by isocratic elution with MeOH to give four
subfractions (F9k3a–F9k3d). F9k3b (1.7 g) was purified repeatedly
by semipreparative HPLC (55% CH3CN/H2O, 3 mL min–1) to af-
ford compounds 19 (8 mg, tR = 13 min), 3 (1.5 mg, tR = 20 min),
4 (1.0 mg, tR = 22 min), 5 (0.8 mg, tR = 23 min), and 10 (3.6 mg,
tR = 24 min).
Argyinolide B (2): White powder. [α]2D1 = +162.1 (c = 0.45, MeOH).
ECD (CH3CN): 227 (Δε = +25.1), 263 (Δε = –0.49), 322 (Δε =
–1.7). 1H NMR and 13C NMR spectroscopic data: see Table 1 and
Table 2. IR (KBr): νmax = 3436, 2964, 2931, 1767, 1721, 1691, 1628,
˜
1378, 1259, 1164, 1121, 1028, 1006 cm–1. HRMS (ESI, +): calcd.
for C17H20O6Na [M + Na]+ 343.1158; found 343.1152.
Argyinolide C (3): White powder. [α]2D1 = +82.2 (c = 0.22, MeOH).
ECD (MeOH): 212 (Δε = –1.1), 265 (Δε = –0.4). 1H NMR and 13
C
NMR spectroscopic data: see Table 1 and Table 2. IR (KBr): ν
˜
max
F10 (96 g) was chromatographed on a column of silica gel, with
elution successively with a gradient of PE/EtOAc (4:1, 7:3, 3:2, 1:1,
and 0:1 v/v), to give eight subfractions (F10a–F10 h). F10g (23 g)
was transferred to a reversed-phase C18 silica gel column and eluted
with MeOH/H2O (2:3, 3:2, and 4:1 v/v) to yield three subfractions
(F10g1–F10g3). During natural evaporation a white crystalline-like
powder precipitated from the mother liquor of F10g1. The residue
was further purified by semipreparative HPLC (20% CH3CN/H2O,
3 mLmin–1) to afford compounds 6 (10 mg, tR = 37 min) and 7
(2 mg, tR = 35 min). F10g2 (5.7 g) was purified repeatedly by semi-
preparative HPLC (CH3CN/H2O, 3 mL min–1) to afford com-
pounds 12 (3.6 mg, tR = 39 min, 25% CH3CN/H2O), 8 (2.0 mg, tR
= 42 min, 40% CH3CN/H2O), and 9 (3.0 mg, tR = 26 min, 45%
CH3CN/H2O).
= 3404, 2958, 2926, 1755, 1725, 1663, 1632, 1459, 1376, 1278, 1160,
1058, 1006 cm–1. HRMS (ESI, –): calcd. for C20H27O6Cl2
[M + Cl]– 433.1190; found 433.1199.
Argyinolide D (4): White powder. [α]2D1 = +88.0 (c = 0.16, MeOH).
ECD (MeOH): 227 (Δε = +2.9), 258 (Δε = –1.6). 1H NMR and
13C NMR spectroscopic data: see Table 1 and Table 2. IR (KBr):
ν
= 3432, 2927, 1753, 1722, 1626, 1459, 1383, 1250, 1151,
˜
max
1059 cm–1. HRMS (ESI, –): calcd. for C20H27O6Cl2 [M + Cl]–
433.1190; found 433.1201.
Argyinolide E (5): White powder. [α]2D1 = +91.8 (c = 0.24, MeOH).
1
ECD (MeOH): 223 (Δε = +18.2), 258 (Δε = –0.4). H NMR and
13C NMR spectroscopic data: see Table 1 and Table 2. IR (KBr):
ν
max = 3433, 2927, 1756, 1712, 1644, 1455, 1231, 1146, 1066, 1038,
˜
1008 cm–1. HRMS (ESI, –): calcd. for C20H25O6Cl2 [M + Cl]–
431.1034; found 431.1047.
Argyinolide A (1): Off-white amorphous powder. [α]2D1 = +118.0 (c
= 0.26, MeOH). ECD (MeOH): 227 (Δε = –3.2), 265 (Δε = –0.7).
1H NMR and 13C NMR spectroscopic data: see Table 1 and
Argyinolide F (6): White powder. [α]2D1 = –15.5 (c = 0.48, MeOH).
1
ECD (MeOH): 230 (Δε = +0.2). H NMR and 13C NMR spectro-
Table 2. IR (KBr): νmax = 3441, 2920, 1772, 1720, 1635, 1256, 1142,
˜
1033 cm–1. HRMS (ESI, +): calcd. for C17H20O5Na [M + Na]+
327.1203; found 327.1208, calcd. for C17H24NO5 [M + NH4]+
322.16490; found 322.16436.
scopic data: see Table 1 and Table 2. IR (KBr): ν
= 3489, 3390,
˜
max
2923, 1772, 1717, 1657, 1452, 1376, 1260, 1168, 1049, 994 cm–1.
HRMS (ESI, –): calcd. for C17H24O6Cl [M + Cl]– 359.1267; found
359.1256.
Preparation of (R)- and (S)-MTPA Esters of 1 by the “in-NMR-
tube” Mosher Ester Procedure: Compound 1 (0.45 mg) was trans-
ferred to a clean NMR tube and dried completely in a vacuum
drying oven. Deuterated pyridine (0.5 mL) and (R)-MTPA chloride
(5 μL) were added to the NMR tube immediately under a N2 gas
stream, and the NMR tube was then shaken rigorously to mix the
sample and MTPA chloride evenly. The NMR tube was permitted
to stand at room temperature and monitored every 2 h by 1H NMR
X-ray Crystallographic Analysis of 6: Upon crystallization from
methanol by use of the vapor diffusion method, colorless crystals
of 6 were obtained. A crystal (0.31ϫ0.38ϫ0.51 mm) was sepa-
rated from the sample and data were collected with a Rigaku
MicroMax 002+ diffractometer and use of Cu-Kα radiation and the
ω and κ scan technique to a maximum 2θ value of 144.48°. Crystal
data: C17H24O6, M = 324.37, monoclinic, P21, a = 10.160 (3) Å, b
Eur. J. Org. Chem. 2014, 973–983
© 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
www.eurjoc.org
981